Newsroom

The antimicrobial potential of CRISPR-Cas systems is promising, yet how to best design or implement CRISPR nucleases remains poorly understood. An international team led by the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg has now addressed this knowledge gap. The researchers conducted the first systematic interrogation of CRISPR antimicrobials using multidrug-resistant and hypervirulent bacteria as case studies, revealing wide variations in efficacy that could be predicted via high-throughput screening and machine learning. Their findings were published today in the journal Nucleic Acids Research.

The so-called B cells are part of the immune system's memory. Their memories of previous infections or vaccinations provide the template for antibodies that have a protective effect the next time they come into contact with a pathogen. Researchers at TWINCORE, Centre for Clinical and Experimental Infection Research, have now been able to show that the combination of infection and subsequent vaccination in the case of the SARS-CoV-2 coronavirus even protects against future variants of the virus by the memory cells virtually predicting the future. The team describes how this works in the European Journal of Immunology. The TWINCORE is a joint institution of the Helmholtz Centre for Infection Research (HZI) in Braunschweig and Hannover Medical School (MHH).

Scientists at the Helmholtz Centre for Infection Research (HZI) rely on working with laboratory animals to research infectious diseases in more detail and to understand the complex interactions between pathogens and their hosts. To this end, the HZI operates a central animal facility for breeding and keeping mice and hamsters.

Leukemia is the most common cancer in children. Cancer treatment severely weakens the children's immune system and they can easily develop opportunistic infections. One of the most common causes of such complications is the cytomegalovirus (CMV) from the herpes virus family. The department “Viral Immunology” headed by Prof. Luka Cicin-Sain at the Helmholtz Centre for Infection Research (HZI) in Braunschweig is now investigating immunotherapy options against CMV. The project is enabled by a donation from the Günter Hansmeier Krebsstiftung in Braunschweig, which is funding the position of a doctoral researcher for three years.

Fabian Leendertz, Director of the Helmholtz Institute for One Health (HIOH) in Greifswald, and his team have been working for more than a decade in the south of the Central African Republic, in the Dzanga Sangha Conservation Areas. As part of a close collaboration with the WWF of the Central African Republic, the HIOH supports the monitoring of the health status of wildlife in these protected areas, with a focus on lowland gorillas. Over the years, activities have been expanded to better characterize the interface between humans, animals and the environment in this extraordinary ecosystem.

One would expect a high school graduate to have little time for extracurricular activities shortly before the final written exams. Nevertheless, Alexander Becker can regularly be found in the laboratories of the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), even at this time of year. HIPS is a site of the Helmholtz Centre for Infection Research (HZI) in collaboration with Saarland University. There, the 18-year-old student from the Gymnasium am Stefansberg in Merzig is trying to isolate myxobacteria from unusual soil samples. His work is part of a project with which he successfully took part in the Jugend forscht competition for young scientists. Together with ten other students from Saarland, he qualified for the 59th national Jugend forscht competition, which will take place in Heilbronn from May 30 to June 2, 2024.